Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alberto Serrano-Pozo, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Alberto Serrano-Pozo and Matthew Frosch.
Connection Strength

1.674
  1. Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. J Neuropathol Exp Neurol. 2016 06; 75(6):516-26.
    View in: PubMed
    Score: 0.169
  2. Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. Am J Pathol. 2016 Feb; 186(2):375-84.
    View in: PubMed
    Score: 0.165
  3. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol. 2014 Apr; 75(4):597-601.
    View in: PubMed
    Score: 0.147
  4. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol. 2013 Dec; 72(12):1182-92.
    View in: PubMed
    Score: 0.143
  5. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol. 2013 Jun; 72(6):462-71.
    View in: PubMed
    Score: 0.139
  6. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol. 2013 Jun; 182(6):2332-44.
    View in: PubMed
    Score: 0.137
  7. Stable size distribution of amyloid plaques over the course of Alzheimer disease. J Neuropathol Exp Neurol. 2012 Aug; 71(8):694-701.
    View in: PubMed
    Score: 0.131
  8. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a006189.
    View in: PubMed
    Score: 0.123
  9. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol. 2011 Sep; 179(3):1373-84.
    View in: PubMed
    Score: 0.122
  10. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain. 2010 May; 133(Pt 5):1312-27.
    View in: PubMed
    Score: 0.111
  11. Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nat Med. 2021 Feb; 27(2):356.
    View in: PubMed
    Score: 0.059
  12. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nat Med. 2020 08; 26(8):1256-1263.
    View in: PubMed
    Score: 0.056
  13. Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease. Acta Neuropathol Commun. 2014 Oct 21; 2:146.
    View in: PubMed
    Score: 0.038
  14. Studying synapses in human brain with array tomography and electron microscopy. Nat Protoc. 2013; 8(7):1366-80.
    View in: PubMed
    Score: 0.035
  15. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid ß peptide. J Neurosci. 2012 Oct 24; 32(43):15181-92.
    View in: PubMed
    Score: 0.033
  16. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012 Oct; 181(4):1426-35.
    View in: PubMed
    Score: 0.033
  17. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-ß. Brain. 2012 Jul; 135(Pt 7):2155-68.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.